NIH Grants: Fund Your Biodefense Research
Summary
Small businesses and research institutions can secure up to $20 million to develop vital vaccines, therapeutics, or diagnostics for critical biodefense agents. This funding supports the preclinical development of innovative solutions against NIAID Category A, B, or C priority agents.
Eligibility
Full Description
Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications for projects that support preclinical development of lead candidate vaccines, therapeutics, adjuvants or diagnostics against NIAID Category A, B, or C priority agents. Mechanism of Support. This FOA will utilize the R01 award mechanism.
Funds Available and Anticipated Number of Awards. The NIAID intends to commit $20.0 million in total costs in FY2011 to fund fifteen to twenty applications in response to this FOA.